Tuğba Başoğlu, Associate Professor at Kartal Dr. Lutfi Kirdar City Hospital, shared Oncology Brothers’s post on X:
“FDA approval alert!
Dato-DXd has been approved for previously treated EGFR-mutant NSCLC based on pooled data from tropionlung 01 and 05.
- ORR: 43%
- mDOR: 7.0 mo
- mPFS: 5.8 mo
- mOS: 15.6 mo
A new chapter for ADCs in EGFR+ NSCLC begins.”
Quoting Oncology Brothers’s post:
“Datopotamab deruxtecan (DatoDXd – Trop2 ADC) now FDA Oncology approved off TROPION Lung 01 and 05 for previously treated mEGFR NSCLC
- ORR of 42.7%, mDoR 7.0 mos
- mPFS: 5.8 mos and mOS 15.6 mos
- AEs: Nausea, stomatitis, and ILD”
An interesting article about NSCLC.